General Notices

• Notice of Pre-Application Webinar for RFA-DK-21-034, Analysis, Technology, Leadership, Administration and Science (ATLAS) Center (U24 Clinical Trial Not Allowed)
  (NOT-DK-22-006)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of Clarification of Reporting Requirements for Animal Welfare Act Regulated Institutions, "Guidance on Flexibilities for Conducting Semiannual Inspections of Animal Facilities"
  (NOT-OD-22-048)
  Office of the Director, NIH
  

Notice of Changes to Funding Opportunities

• Notice to Expire NOSIs to PAR-19-070, "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)"
  (NOT-AG-22-006)
  National Institute on Aging
  

• Notice to Expire NOSIs to PAR-19-071, "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Not Allowed)"
  (NOT-AG-22-007)
  National Institute on Aging
  

• Notice of NCI's Participation in PAR-20-070, "Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33 - Clinical Trial Optional)"
  (NOT-CA-22-023)
  National Cancer Institute
  

• Notice to Extend the Response Date for NOT-CA-22-004 "Request for Information (RFI): Seeking Input on Technology Needs for Cancer Control and Population Sciences Researchers"
  (NOT-CA-22-024)
  National Cancer Institute
  

• Notice of NHLBI Participation in PAR-21-169 Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)
  (NOT-HL-21-042)
  National Heart, Lung, and Blood Institute
  

• Notice of NHLBI Participation in PAR-21-173 - "Support for Research Excellence First Independent Research (SuRE-First) Award (R16 - Clinical Trial Not Allowed)"
  (NOT-HL-21-043)
  National Heart, Lung, and Blood Institute
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: Restoring Joint Health and Function to Reduce Pain Consortium (RE-JOIN) (UC2 Clinical Trial Not Allowed)
  (NOT-AR-22-015)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Center for Complementary and Integrative Health
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Dental and Craniofacial Research
  National Institute of Neurological Disorders and Stroke
  

Requests for Proposal

• Request for Proposals FNIH Cancer Steering Committee Project Concepts for Novel Biomarker Platforms to Support Novel Tissue Imaging, Remote Sensing, and Toxicity Challenges
  (NOT-CA-22-028)
  National Cancer Institute
  

Notices of Special Interest

• Notice of Special Interest: Research on Pain, Pain Management, and Opioids in Aging
  (NOT-AG-22-004)
  National Institute on Aging
  

• Notice of Special Interest (NOSI): Availability of Administrative Supplements for Research on Pain, Pain Management, and Opioids in Aging
  (NOT-AG-22-005)
  National Institute on Aging
  

• Notice of Special Interest: NCCIH High Priority Pain Research
  (NOT-AT-22-007)
  National Center for Complementary and Integrative Health
  

• Notice of Special interest (NOSI): Medications Development for Stimulant Use Disorders
  (NOT-DA-22-049)
  National Institute on Drug Abuse
  

• Notice of Special Interest (NOSI): Promoting Fundamental Research on Mitochondrial Involvement in Lung Diseases and Sleep Disorders
  (NOT-HL-22-003)
  National Heart, Lung, and Blood Institute
  

• Notice of Special Interest (NOSI) Pediatric COVID-19 and Respiratory Viral Co-infection
  (NOT-HL-22-004)
  National Heart, Lung, and Blood Institute
  National Institute of Allergy and Infectious Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  

• RESCINDED - Notice of Special Interest (NOSI): Diagnostics and Disease Management Tools for Use in Underserved Populations
  (NOT-HL-22-006)
  National Heart, Lung, and Blood Institute
  

• Notice of Special Interest (NOSI): Epidemiologic studies in Asian Americans, Native Hawaiians, and Pacific Islanders (Parent R01 Clinical Trial Not Allowed)
  (NOT-HL-23-001)
  National Heart, Lung, and Blood Institute
  National Cancer Institute
  National Human Genome Research Institute
  National Institute on Aging
  National Institute of Environmental Health Sciences
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  

• RESCINDED - Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities
  (NOT-MD-22-006)
  National Institute on Minority Health and Health Disparities
  National Cancer Institute
  National Institute of Allergy and Infectious Diseases
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Mental Health
  National Institute of Nursing Research
  Office of Behavioral and Social Sciences Research
  Office of Disease Prevention
  Office of Research on Women's Health
  

• Notice of Special Interest (NOSI): NIMH Administrative Supplement Program to Enable Continuity of Research Experiences of MD/PhDs during Clinical Training (Admin Supp Clinical Trial Optional)
  (NOT-MH-22-060)
  National Institute of Mental Health
  

• RESCINDED - Notice of Special Interest (NOSI): Pain-Focused Administrative Supplements for NINDS Grants that are Not Focused on Pain Research
  (NOT-NS-22-053)
  National Institute of Neurological Disorders and Stroke
  

Funding Opportunities

• NIA Renewal and Revision Cooperative Agreements in AD/ADRD Research (U54 Clinical Trial Optional)
  (PAR-22-077)
  National Institute on Aging
  Application Receipt Date(s): October 17, 2024
  
  

• Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)
  (PAR-22-093)
  National Institute on Aging
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): November 12, 2024
  
  

• Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)
  (PAR-22-094)
  National Institute on Aging
  Application Receipt Date(s): November 12, 2024
  
  

• Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)
  (PAS-22-096)
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  Application Receipt Date(s): January 07, 2025
  
  

• Resources to Promote Coordination and Collaboration across Deeply Phenotyped Longitudinal Behavioral and Social Studies of Aging (U24 Clinical Trial Not Allowed)
  (RFA-AG-23-003)
  National Institute on Aging
  Application Receipt Date(s): March 03, 2022
  
  

• Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional)
  (RFA-AI-21-079)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): June 03, 2022
  
  

• HEAL Initiative: Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R01- Clinical Trial Not Allowed)
  (RFA-DA-22-044)
  National Institute on Drug Abuse
  National Center for Complementary and Integrative Health
  National Institute on Aging
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Dental and Craniofacial Research
  Application Receipt Date(s): March 10, 2022
  
  

• HEAL Initiative: Exploratory Data and Methods to Address Urgent Needs to Stem the Opioid Epidemic (R21- Clinical Trial Not Allowed)
  (RFA-DA-22-045)
  National Institute on Drug Abuse
  National Center for Complementary and Integrative Health
  National Institute on Aging
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Dental and Craniofacial Research
  Application Receipt Date(s): March 10, 2022
  
  

• PBPK Modeling to Support an Assessment of Bioequivalence for Locally-Acting Drugs in the Gastrointestinal Tract (U01) Clinical Trial Optional
  (RFA-FD-22-012)
  Food and Drug Administration
  Application Receipt Date(s): March 31, 2022, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date.
  
  

• Physiologically Based Pharmacokinetic Model for Nose-to-Brain Drug Delivery (U01) Clinical Trial Optional
  (RFA-FD-22-016)
  Food and Drug Administration
  Application Receipt Date(s): May 18, 2022 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s) No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Cutaneous Pharmacokinetics (PK) Based Approaches to Demonstrate Bioequivalence of Topical Products (U01) Clinical Trial Required
  (RFA-FD-22-017)
  Food and Drug Administration
  Application Receipt Date(s): March 31, 2022, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date.
  
  

• Building an Integrated Information Technology Infrastructure for State Regulatory Programs (U2F) [Clinical Trial Not Allowed]
  (RFA-FD-22-021)
  Food and Drug Administration
  Application Receipt Date(s): February 22, 2022
  
  

• Social disconnection and Suicide Risk in Late Life (R01 Clinical Trial Optional)
  (RFA-MH-22-135)
  National Institute of Mental Health
  National Institute on Aging
  Application Receipt Date(s): October 17, 2022
  
  

• Social disconnection and Suicide Risk in Late Life (R21 Clinical Trial Optional)
  (RFA-MH-22-136)
  National Institute of Mental Health
  National Institute on Aging
  Application Receipt Date(s): October 15, 2022